24小时热门版块排行榜

返回列表

【有奖交流】积极回复本帖子，参与交流，就有机会分得作者 vnyh3993 的 31 个金币，回帖就立即获得 1 个金币，每人有 1 次机会

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

vnyh3993

新虫 (小有名气)

应助: 0 (幼儿园)
金币: 361
帖子: 102
在线: 3.3小时
虫号: 24277795

[交流] IgY-Technology英文专著在Springer出版

IgY-Technology: Production and Application of Egg Yolk Antibodies: Basic Knowledge for a Successful Practice

近日，IgY抗体技术专著（IgY-Technology: Production and Application of Egg Yolk Antibodies: Basic Knowledge for a Successful Practice, Springer Nature Group, Switzerland. 2021. ISBN: 978-3-030-72686-7. https://www.springer.com/gp/book/9783030726867#aboutBook）在Springer出版社出版，该书是全球范围内第一部针对IgY抗体技术的系统性英文学术专著，由张小莺教授领衔主编，联合近二十个国家的四十多位学者历时多年编撰而成。

专著链接：https://www.springer.com/gp/book/9783030726867#aboutBook

该专著共18章，系统性的回顾和总结了IgY抗体技术的发展历程、技术特点和发展前沿，涉及理论基础、技术方法学及生物医药领域的研发应用。专著覆盖了IgY技术相关的各个领域，如进化视野下的IgY分子机制、受体与转运机制、免疫技术、IgY抗体的不同提取纯化策略、储存稳定性、工业化生产、在人类和兽医领域中的应用、IgY递送策略、IgY基因工程抗体制备、转基因动物开发、IgY产品报批及产业化，技术局限与创新等。

近年来，IgY抗体技术（卵黄抗体技术）不断发展，具备了相对完备统一的技术模式；不断与现代生物学技术相结合，拓展技术自生的内涵和外延；相关产品在世界范围内不断报批问世，形成了一定的产业基础。

据悉，科学出版社将与张小莺教授团队合作，在2011年中文版的基础上，适时推出IgY抗体技术中文第二版，以供中国读者和研究人员参考、交流。

图书信息
This first edited Volume on IgY-Technology, addresses the historical and dynamic development of IgY-applications. The authors cover the biological basis and theoretical context, methodological guidance, and applications of IgY-Technology. A focus is laid on the use of IgY-antibodies for prophylactic/therapeutic purposes in human and veterinary medicine.
Aside from applications, the chapters also offer an evolutionary understanding of the IgY molecule, IgY receptors and practical prerequisites to produce IgY-antibodies. Guidance is given for every step of the process. Starting with an introduction to hens as a model species and including hen husbandry, hen egg-laying capacity and total IgY outcomes. Readers will also learn about immunization techniques, the advantages and limitations of different IgY extraction methods, as well as storage stability of the final product.
The last part of the volume highlights hands-on aspects of applications, such as IgY delivery strategies, new methods to produce monoclonal IgY-antibodies or production of functional IgY fragments by phage-display as well as commercial exploitation of the technology. Thus, this book is a valuable resource and guide for Scientists, Clinicians and Health Product Developers in both human and veterinary medicine.

主编信息
Prof. Dr. Xiaoying ZHANG, PhD in Pharmacology (Charité Medical University Berlin), Distinguished Professor at Shaanxi Univ. of Technology (2019-present); Senior Researcher at CBMA, Univ. of Minho, Portugal (2016-present); Professor (Adjunct) at Univ. of Guelph, Canada (2017-present); Professor at Northwest Agricultural & Forestry Univ., China (2008-2018). He has been dedicated to the development, popularisation and application of IgY Technology.

Ricardo S. Vieira-Pires is an Assistant Investigator at the Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Portugal. He obtained his PhD in Structural Biology (2008) at University Joseph Fourier, Grenoble, France. He is head of the Structural Biotechnology Group that studies proteins and molecular assemblies involved in key processes of bacterial and viral infectious diseases. He is particularly interested in targeting microbial surface-exposed virulent factors using antibodies. He is head of the CNC – Avian Technological Unit that explores bird immune repertoires for antibody discovery. He is engaged with academic and industry partners promoting IgY Technology-based solutions for human and veterinary medicine.

Patricia M. Morgan is an Emerita Senior Lecturer at the National University of Ireland Galway (NUI Galway). Having been awarded a PhD in Biochemistry at NUI Galway, she undertook post-doctoral research at the University of Wisconsin-Madison, USA in the areas of reproductive biology and endocrinology. She has held senior positions at NUI Galway as Dean of the College of Science and Dean of Graduate Studies. In these posts, she has championed research developments within the University particularly in the areas of Biotechnology and Innovation. She has served on various national committees promoting science and is an advocate for the public understanding of science and the promotion of inclusion and diversity in academia.

Rüdiger Schade started his scientific career at the Institute of Pharmacology, Charité – Universitätsmedizin in Berlin, Germany, in 1976. Since the early 1990’s, his research has been strongly focused on the development, production and application of IgY antibodies. His contributions significantly influenced the field of IgY-technology and promoted the application of this technology worldwide, particularly in Latin-America. In acknowledgement of his research efforts, he received the FISEA prize – the International Foundation for the Substitution of Animal Experimentation, Luxemburg - in 1997.

回复此楼